RGNX — Regenxbio Inc

Regenxbio Inc (RGNX) is a biotechnology company listed on NASDAQ. It is led by Curran M. Simpson M.S., based in 9804 Medical Center Drive, Rockville, MD, United States, 20850, with about 353 employees. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Latest reported RGNX revenue for 2025-09-30 was $29.7M. Net income was -$126.7M. Revenue was up 39.2% from 2025-06-30 to 2025-09-30. RGNX currently screens at market cap $440.4M.

Use this RGNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RGNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RGNX SEC filings page. Lician reads the product cache first so this HTML stays unique to Regenxbio Inc even when a live quote feed is slow.